Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
RBC Capital Cuts Price Target on Endo Int'l (ENDP) Following Guidance Update
September 29, 2015 7:42 AM EDTRBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
September 28, 2015 11:24 AM EDTGuggenheim reiterated a Buy rating and $110.00 price target on Endo International plc (NASDAQ: ENDP) following the company's updated financial guidance. Analyst Louise Chen continues to believe ENDP has set the stage for better-than-expected growth in '16+ driven by Xiaflex, Belbuca and the generics... More
Endo Int'l (ENDP) Closes Par Pharma Acquisition; Updates Guidance
September 28, 2015 6:34 AM EDTEndo Int'l (NASDAQ: ENDP) announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. from leading global private investment firm TPG.
Through this acquisition, Endo has further established its position as a leading global specialty pharmaceutical company with a fast growing generics business that is among the top five as measured by U.S. sales according to IMS. The acquisition also helps position Endo for long-term double-digit organic growth, enhanced cash flow generation and increased financial flexibility. Endo's generics portfolio now includes an extensive range of in market and... More
